Julie Rinkenberger

Title: Innovations of Julie Rinkenberger

Introduction

Julie Rinkenberger is a notable inventor based in Moraga, California. She has made significant contributions to the field of biotechnology, particularly in the development of targeted binding agents. With a total of three patents to her name, her work has implications for medical advancements.

Latest Patents

Rinkenberger's latest patents focus on antibodies directed to the antigen αVβ6 and their various uses. These patents describe fully human monoclonal antibodies that target the αVβ6 antigen. The patents also disclose nucleotide sequences encoding heavy and light chain immunoglobulin molecules. Specifically, they cover sequences that correspond to contiguous heavy and light chain sequences spanning the framework regions and complementarity determining regions (CDRs). Additionally, the patents detail hybridomas or other cell lines that express these immunoglobulin molecules and monoclonal antibodies.

Career Highlights

Throughout her career, Rinkenberger has worked with prominent companies in the pharmaceutical industry. She has been associated with MedImmune Limited and Bayer Pharmaceutical Corporation, where she contributed to innovative research and development projects. Her expertise in biotechnology has positioned her as a valuable asset in her field.

Collaborations

Rinkenberger has collaborated with notable professionals, including Ian Nevin Foltz and Avril Alfred. These collaborations have further enhanced her research and development efforts in the biotechnology sector.

Conclusion

Julie Rinkenberger's contributions to the field of biotechnology through her patents and collaborations highlight her innovative spirit and dedication to advancing medical science. Her work continues to influence the development of targeted therapies.